Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

被引：0

作者：

Yildirim, Hasan Cagri ^{[1
]}

Bayram, Ertugrul ^{[2
]}

Chalabiyev, Elvin ^{[3
]}

Majidova, Nargiz ^{[4
]}

Avci, Tugay ^{[5
]}

Guzel, Halil Goksel ^{[6
]}

Kapar, Caner ^{[7
]}

Uzun, Mehmet ^{[8
]}

Perkin, Perihan ^{[9
]}

Akgul, Fahri ^{[10
]}

Yildirim, Saadet Sim ^{[11
]}

Sali, Seda ^{[12
]}

Yildiz, Anil ^{[13
]}

Kazaz, Seher Nazli ^{[14
]}

Hendem, Engin ^{[15
]}

Arcagok, Murat ^{[16
]}

Tufan, Gulnihal ^{[17
]}

Yildirim, Umit ^{[18
]}

Akgul, Omer Faruk ^{[19
]}

Arslan, Cagatay ^{[20
]}

Taban, Hakan ^{[21
]}

Sahin, Eren ^{[22
]}

Caglayan, Melek ^{[23
]}

Esen, Ramazan ^{[18
]}

Oksuzoglu, Berna ^{[17
]}

Guven, Deniz Can ^{[3
]}

Kaplan, Muhammet Ali ^{[16
]}

Araz, Murat ^{[15
]}

Basaran, Mert ^{[13
]}

Cubukcu, Erdem ^{[12
]}

Gokmen, Erhan ^{[11
]}

Cicin, Irfan ^{[10
]}

Algin, Efnan ^{[9
]}

Semiz, Huseyin Salih ^{[8
]}

Tural, Deniz ^{[7
]}

Ozturk, Banu ^{[6
]}

Erdogan, Atike Pinar ^{[5
]}

Sari, Murat ^{[4
]}

Kara, Oguz ^{[2
]}

Erman, Mustafa ^{[3
]}

机构：

[1] Nigde Educ & Res Hosp, Dept Med Oncol, Nigde, Turkiye

[2] Cukurova Univ, Fac Med, Dept Med Oncol, Adana, Turkiye

[3] Hacettepe Univ, Canc Inst, Dept Med Oncol, Ankara, Turkiye

[4] Marmara Univ, Fac Med, Dept Med Oncol, Istanbul, Turkiye

[5] Celal Bayar Univ, Fac Med, Dept Med Oncol, Manisa, Turkiye

[6] Antalya Educ & Res Hosp, Dept Med Oncol, Antalya, Turkiye

[7] Bakirkoy Dr Sadi Konuk Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkiye

[8] Eylul Univ, Fac Med 9, Dept Med Oncol, Izmir, Turkiye

[9] Yildirim Beyazit Univ, Bilkent State Hosp, Dept Med Oncol, Ankara, Turkiye

[10] Trakya Univ, Fac Med, Dept Med Oncol, Edirne, Turkiye

[11] Ege Univ, Fac Med, Dept Med Oncol, Izmir, Turkiye

[12] Uludag Univ, Fac Med, Dept Med Oncol, Bursa, Turkiye

[13] Istanbul Univ, Inst Oncol, Dept Med Oncol, Istanbul, Turkiye

[14] Med Pk Hosp, Dept Med Oncol, Trabzon, Turkiye

[15] Necmettin Erbakan Univ, Meram Fac Med, Dept Med Oncol, Konya, Turkiye

[16] Dicle Univ, Fac Med, Dept Med Oncol, Diyarbakir, Turkiye

[17] Univ Hlth Sci, Dr AY Ankara Oncol Res & Educ Hosp, Dept Med Oncol, Ankara, Turkiye

[18] Yuzuncu Yil Univ, Fac Med, Dept Med Oncol, Van, Turkiye

[19] Adnan Menderes Univ, Fac Med, Dept Med Oncol, Aydin, Turkiye

[20] Medicalpoint Hosp, Dept Med Oncol, Izmir, Turkiye

[21] Samsun Training & Res Hosp, Dept Med Oncol, Samsun, Turkiye

[22] Akdeniz Univ, Fac Med, Dept Med Oncol, Antalya, Turkiye

[23] Selcuk Univ, Fac Med, Dept Med Oncol, Konya, Turkiye

来源：

JOURNAL OF CHEMOTHERAPY | 2024年

关键词：

Non-clear cell renal cell carcinoma; sunitinib; pazopanib; TKIs; rare tumors; papillary RCC; OPEN-LABEL; 1ST-LINE PAZOPANIB; MULTICENTER; INHIBITOR; THERAPY; CANCER;

D O I：

10.1080/1120009X.2024.2403051

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Non-clear cell renal cell carcinoma (non-ccRCC) is a highly heterogeneous disease group, accounting for approximately 25% of all RCC cases. Due to its rarity and especially heterogeneity, phase III trial data is limited and treatment options generally follow those of clear cell RCC. In the literature, there exists a number of studies with sunitinib, cabozantinib, and everolimus, but data on the efficacy of pazopanib are limited. Our aim in this study was to compare the efficacy of pazopanib and sunitinib, in a multicenter retrospective cohort of non-ccRCC patients. Our study included patients diagnosed with non-ccRCC who received pazopanib or sunitinib treatment as first-line therapy from 22 tertiary hospitals. We compared the progression-free survival (PFS), overall survival (OS), and response rates of pazopanib and sunitinib treatments. Additionally, we investigated prognostic factors in non-ccRCC. PFS and response rates of sunitinib and pazopanib were found to be similar, while a numerical difference was observed in OS. Being 65 years and older, being in the intermediate or poor risk group according to the International Metastatic Renal Cell Carcinoma Database Consortium, having liver metastases, presence of a sarcomatoid component, and having de novo metastatic disease were found to be significantly associated with shorter PFS. Pazopanib treatment appears to have similar efficacy in the treatment of non-ccRCC compared to sunitinib. Though randomized controlled trials are lacking and will probably be never be available, we suggest that pazopanib could be a preferred agent like sunitinib and cabozantinib. Pazopanib and sunitinib treatments show similar progression free survival, overall survival and objective response rate.IMDC risk group, liver metastasis, sarcomatoid component and de novo metastatic disease were determined as prognostic factors

引用

页数：12

共 50 条

[21] Multicenter prospective phase II study of sunitinib in non-clear cell type renal cell carcinoma
Lee, J.
Ahn, J.
Lim, H.
Lee, S.
Kim, T.
Lee, D.
Cho, Y. M.
Hong, J.
Kim, C.
Ahn, H.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
[22] Outcomes of Patients With Advanced Renal Cell Carcinoma With Non-Clear Cell Histology Treated With Systemic Therapy
Urman, Danielle
Deshler, Leah
Weise, Nicole
Shabaik, Ahmed
Derweesh, Ithaar
Bagrodia, Aditya
Rose, Brent
Herchenhorn, Daniel
McKay, Rana R.
CLINICAL GENITOURINARY CANCER, 2023, 21 (06) : 660 - 668.e1
[23] Neoadjuvant Temsirolimus Effectiveness in Downstaging Advanced Non-Clear Cell Renal Cell Carcinoma
Rodriguez Faba, Oscar
Breda, Alberto
Rosales, Antonio
Palou, Joan
Algaba, Ferran
Maroto Rey, Pablo
Villavicencio, Humberto
EUROPEAN UROLOGY, 2010, 58 (02) : 307 - 310
[24] RETRACTED: Advanced Treatments in Non-Clear Renal Cell Carcinoma (Retracted Article)
Tazi, El Mehdi
Essadi, Ismail
Fadl Tazi, Mohamed
Ahellal, Youness
M'Rabti, Hind
Errihani, Hassan
UROLOGY JOURNAL, 2011, 8 (01) : 1 - 11
[25] The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC)
Stadler, W. M.
Figlin, R. A.
Ernstoff, M. S.
Curti, B.
Pendergrass, K.
Srinivas, S.
Canfield, V.
Weissman, C.
Poulin-Costello, M.
Bukowski, R. M.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[26] Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?
Bonadio, Renata Colombo
Velho, Pedro Isaacsson
Marta, Guilherme Nader
Narda, Mirella
La Souza, Manoel Carlos
Muniz, David Q. B.
Bezerra, Regis O. F.
Bispo, Raisa K. A.
Faraj, Sheila F.
Bastos, Diogo A.
Dzik, Carlos
ECANCERMEDICALSCIENCE, 2019, 13
[27] Therapeutic approaches in clear cell and non-clear cell renal cell carcinoma
Vermassen, T.
De Meulenaere, A.
Van de Walle, M.
Rottey, Sylvie
ACTA CLINICA BELGICA, 2017, 72 (01) : 12 - 18
[28] Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
Goldstein, David
Rosenberg, Jonathan E.
Figlin, Robert A.
Townsend, Raymond R.
McCann, Lauren
Carpenter, Christopher
Pandite, Lini
EUROPEAN JOURNAL OF CANCER, 2016, 53 : 96 - 104
[29] Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Koshkin, Vadim S.
Barata, Pedro C.
Zhang, Tian
George, Daniel J.
Atkins, Michael B.
Kelly, William J.
Vogelzang, Nicholas J.
Pal, Sumanta K.
Hsu, JoAnn
Appleman, Leonard J.
Ornstein, Moshe C.
Gilligan, Timothy
Grivas, Petros
Garcia, Jorge A.
Rini, Brian I.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[30] ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma
Armstrong, Andrew J.
Halabi, Susan
Eisen, Tim
Stadler, Walter Michael
Jones, Robert R.
Vaishampayan, Ultra N.
Garcia, Jorge A.
Hawkins, Robert E.
Kollmannsberger, Christian K.
Lusk, Christine
Broderick, Samuel
George, Daniel J.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →